You are here

Clinical Trials

Tirasemtiv did not differentiate itself from placebo in phase 3 study
Instead of targeting CD19 on the surface of cancer cells, new approach targets CD22
Five sepsis deaths had been reported in late-phase trials
Acorda Therapeutics hits pause on trial enrollment for tozadenant
Compared with placebo, depression scores fell at 60 hours
Risk of death in advanced cases is 26% lower than Afinitor
Patients with cardiovascular issues benefit
Study results fail to justify continued development
Biologic reduced attacks and improved lung function across a broad population
They also had significantly fewer new brain lesions versus those on interferon beta-1a
Subgroup analysis demonstrates improvement in patients who experienced at least one attack per week while on placebo
Updated data show median overall survival of 30.0 months
ALK-positive and ROS1-positive patients benefit
Application to FDA expected in early 2018
“Unfortunate” outcome in phase 3 JUNIPER trial of abemaciclib